A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
Status:
Completed
Trial end date:
2019-03-26
Target enrollment:
Participant gender:
Summary
This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the
safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72
participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination
[MMSE] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered
after the completion of initial double-blind stage.